Shannon Shisler

Shannon Shisler

Auto-generated profile, based on publicly available information

Shannon Shisler

Research Institute on Addictions, University at Buffalo, State University of New York, Buffalo, NY

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Educational Research Review
Verified
Journal Article
Closed access
AAAriel M. Aloe
Ariel M. Aloe
SSShannon M. Shisler
Shannon M. Shisler
BNBenjamin D. Norris
Benjamin D. Norris
ANAmanda B. Nickerson
Amanda B. Nickerson
TRTyler W. Rinker
Tyler W. Rinker

1 September 2010 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
TGTeresa R Gray
Teresa R Gray
RERina D Eiden
Rina D Eiden
KLKenneth E Leonard
Kenneth E Leonard
GCGerard J Connors
Gerard J Connors
SSShannon Shisler
Shannon Shisler
MHMarilyn A Huestis
Marilyn A Huestis
BACKGROUND: Cannabis is the most frequently used illicit drug among pregnant women, but data describing the effects of prenatal cannabis exposure and concurrent nicotine and cannabis exposures on neonatal growth are inconsistent. Testing of meconium, the first neonatal feces, offers objective evidence of prenatal cannabis exposure, but the relative ability of meconium testing and maternal self-report to identify affected neonates remains unclear.METHODS: Eighty-six pregnant women provided detailed self-reports of daily cannabis and tobacco consumption throughout pregnancy. Cannabinoids and tobacco biomarkers were identified in oral fluid samples collected each trimester and quantified in meconium at birth.RESULTS: Cannabis-using women were significantly more likely to also consume tobacco, and smoked similar numbers of cigarettes as non–cannabis-using tobacco smokers. As pregnancy progressed, fewer women smoked cannabis and those who continued to use cannabis reported smoking a smaller number of cannabis joints, but positive maternal oral fluid tests cast doubt on the veracity of some maternal self-reports. More neonates were identified as cannabis exposed by maternal self-report than meconium analysis, because many women quit cannabis use after the first or second trimester; meconium was more likely to be positive if cannabis use continued into the third trimester. Cannabis exposure was associated with decreased birth weight, reduced length, and smaller head circumference, even after data were controlled for tobacco coexposure.CONCLUSIONS: Prenatal cannabis exposure was associated with fetal growth reduction. Meconium testing primarily identifies prenatal cannabis exposure occurring in the third trimester of gestation.

28 April 2010 in Nicotine & Tobacco Research
Verified
Journal Article
Closed access
PDF file
TGTeresa R. Gray
Teresa R. Gray
RERina D. Eiden
Rina D. Eiden
KLKenneth E. Leonard
Kenneth E. Leonard
GCGerard Connors
Gerard Connors
SSShannon Shisler
Shannon Shisler
MHMarilyn A. Huestis
Marilyn A. Huestis
Many women continue tobacco use during pregnancy despite known adverse consequences on neonatal growth and development. Testing meconium, the first neonatal feces, for tobacco biomarkers offers objective evidence of prenatal tobacco exposure. However, relationships between the amount, frequency, and timing of cigarette smoking during gestation and tobacco biomarker meconium concentrations and neonatal outcomes are unclear. Eighty-seven pregnant women provided detailed self-reports of daily tobacco consumption throughout pregnancy. Nicotine, cotinine, and trans-3′-hydroxycotinine were quantified in neonatal meconium by liquid chromatography–tandem mass spectrometry. Among nonsmokers, all meconium specimens were negative, whereas nearly all meconium specimens were positive if the mother self-reported tobacco use into the third trimester. Tobacco biomarker concentrations were significantly albeit weakly correlated with mean cigarettes per day in the third trimester. Reduced birth weight, gestational age, or head circumference were observed if meconium contained one or more tobacco biomarkers, but deficits did not correlate with biomarker concentrations. While previously thought to reflect second and third trimester drug exposure, meconium appears to reliably identify only third trimester drug use. While a 10 ng/g nicotine, cotinine, or trans-3′-hydroxycotinine cutoff in meconium was previously proposed to differentiate tobacco-exposed from nonexposed or passively exposed neonates, improved maternal self-reporting techniques in this cohort suggest that a lower cutoff, equivalent to the analytic limits of quantification, is more appropriate.

1 April 2018 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
RERina D. Eiden
Rina D. Eiden
JZJunru Zhao
Junru Zhao
MCMeghan Casey
Meghan Casey
SSShannon Shisler
Shannon Shisler
PSPamela Schuetze
Pamela Schuetze
CCCraig R. Colder
Craig R. Colder

1 July 2018 in Neurotoxicology and Teratology
Verified
Journal Article
Closed access
RERina D. Eiden
Rina D. Eiden
PSPamela Schuetze
Pamela Schuetze
SSShannon Shisler
Shannon Shisler
MHMarilyn A. Huestis
Marilyn A. Huestis

11 April 2017 in Nicotine & Tobacco Research
Verified
Journal Article
Open access
PDF file
SSShannon Shisler
Shannon Shisler
RERina D. Eiden
Rina D. Eiden
DMDanielle S. Molnar
Danielle S. Molnar
PSPamela Schuetze
Pamela Schuetze
MHMarilyn Huestis
Marilyn Huestis
GHGregory Homish
Gregory Homish
Many studies on prenatal tobacco exposure (PTE) effects have relied on single item retrospective measures of PTE. However, it is unclear how these single item measures may relate to more intensive maternal self-reports and to biological markers of maternal use and/or fetal exposure. It is also unclear whether these measures may be more valid predictors of fetal growth (gestational age, birthweight, head circumference, and birth length). Data were obtained from 258 women during their pregnancy. PTE was assessed by four methods: a single item question, a calendar-based self-report measure from each trimester of pregnancy, maternal salivary cotinine assays, and nicotine and metabolites in infant meconium. We hypothesized that the more intensive measures and biological assays would account for additional variance in birth outcomes, above and beyond the single item measure. The single item self-report measure was not related to fetal growth. However, the more intensive calendar based self-report measure and the biological assays of PTE (ie, maternal salivary assays and infant meconium) were significant predictors of poor fetal growth, even with the single item measure in the model. The negative effects of PTE on important child outcomes may be greatly underestimated in the literature as many studies use single item self-report measures to ascertain PTE. Whereas more intensive self-report measures or biological assays may be cost prohibitive in large scale epidemiological studies, using a combination of measures when possible should be considered given their superiority both identifying prenatal smokers and predicting poor fetal growth. The present work underscores the importance of measurement issues when assessing associations between PTE and fetal growth. Results suggest that we may be greatly underestimating the negative effects of prenatal smoking on fetal growth and other important child outcomes if we rely solely on restricted single item self-report measures of prenatal smoking. Researchers should consider more intensive prospective self-report measures and biological assays as viable and superior alternatives to single item self-report measures.